Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer - Related Studies

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

This study has been completed.

Study NCT00003022. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Intraocular Melanoma
		Lung Cancer
		Melanoma (Skin)
		Neuroblastoma
		Retinoblastoma
		Sarcoma

2	Additional conditions recognized in this trial
		Central Nervous System Neoplasms
		Eye Neoplasms
		Lung Neoplasms
		Melanoma
		Meningeal Neoplasms
		Nervous System Neoplasms
		Neuroectodermal Tumors, Primitive, Peripheral

3	More general conditions related to this trial
		Eye Diseases
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neoplasms, Neuroepithelial
		Nervous System Diseases
		Neuroectodermal Tumors
		Neuroectodermal Tumors, Primitive
		Neuroendocrine Tumors
		Nevi and Melanomas
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Retinal Diseases
		Retinal Neoplasms
		Thoracic Neoplasms

4	Additional drug interventions recognized in this trial
		Antibodies
		Antibodies, Monoclonal

5	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

6	Sponsors listed in this trial
		Memorial Sloan-Kettering Cancer Center
		National Cancer Institute (NCI)